Press Releases

November 9, 2018

Receives IDE Approval from U.S. FDA to Initiate Clinical Trial of the SHUNT Liver Diagnostic Kit

HepQuant Receives IDE Approval from U.S. FDA to Initiate Clinical Trial of the SHUNT Liver Diagnostic Kit SAN FRANCISCO (Nov. 9, 2018) – While attending The Liver Meeting® 2018, HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic…

August 2, 2018

Sean Bundy Appointed Director of Regulatory and Quality Affairs

HepQuant Appoints Sean Bundy Director of Regulatory & Quality Affairs Bringing 20 Years in Medical Device and Diagnostics Regulatory and Quality Experience DENVER (Aug. 2, 2018) — HepQuant, LLC,  a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease,…

May 9, 2018

HepQuant Chosen to Advance to InnoSTARS Semifinals in China

HepQuant Selected as a Semifinalist for 2018 InnoSTARS Competition to be Held in China DENVER (May 9, 2018) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, announced today that the company has been named…

April 24, 2018

HepQuant a Finalist for InnoSTARS Denver Competition

HepQuant a Finalist for 2018 InnoSTARS Denver Competition DENVER (April 24, 2018) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, announced today that the company has been named a finalist for the 2018 InnoSTARS Denver…

January 25, 2018

HepQuant and CTI Clinical Trial and Consulting Services Announce First Patient Enrolled in Liver Disease Diagnostic Trial

HepQuant and CTI Clinical Trial and Consulting Services Announce First Patient Enrolled in Liver Disease Diagnostic Trial FOR IMMEDIATE RELEASE [Covington, KY ~ January 25, 2018] HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease…

January 2, 2018

HepQuant to Present Poster as Finalist at RESI San Francisco Innovation Challenge

HepQuant to Present Poster as a Finalist in the RESI San Francisco Innovation Challenge 2018 DENVER (January 2nd, 2017) — HepQuant, LLC,  a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it will present a…

December 13, 2017

HepQuant to Present at the 10th Annual Biotech Showcase

HepQuant to Present at 10th Annual Biotech Showcase Senior Executives Will Also Attend the J.P. Morgan Healthcare Conference DENVER (December 13th, 2017) — HepQuant, LLC,  a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it…

October 12, 2017

HepQuant Presents at Rocky Mountain Life Science Investor and Partnering Conference

HepQuant Presents at the 2017 Rocky Mountain Life Science Investor and Partnering Conference DENVER (October 12th, 2017) — HepQuant, LLC,  a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it presented at the 2017 Rocky Mountain…

September 30, 2017

HepQuant holding its 2017 Scientific Advisory Board Meeting in Washington D.C. on Saturday, October 21st

HepQuant to Hold 2017 Scientific Advisory Board October 21st in Washington, DC DENVER (August 31, 2017) — HepQuant, LLC, a diagnostics company, located in Greenwood Village, CO with unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced today announced it will be holding…

September 28, 2017

HepQuant to Sponsor its First Clinical Study

HepQuant to Sponsor its First Clinical Study Utilizing 3 Investigational Device Exemptions (IDEs) in Clinical Study of Patients with Alcoholic Hepatitis, NASH F3, NASH F4 DENVER (Sep. 28, 2017) — HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients…